Home-based Diabetes-Modified Behavioral Activation Treatment for Low Income Seniors With T2DM

Last updated: August 4, 2025
Sponsor: State University of New York at Buffalo
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Diabetes Mellitus Types I And Ii

Diabetes And Hypertension

Diabetes Prevention

Treatment

Supportive Therapy (Control)

Home DM-BAT

Clinical Study ID

NCT04203147
1R01DK118038-01A1
  • Ages > 65
  • All Genders

Study Summary

The objective of this protocol is to evaluate the efficacy and cost-effectiveness of 8 sessions of in-home, telephone-delivered, culturally-modified, manualized diabetes-modified, behavioral activation treatment (Home DM-BAT) delivered by trained diabetes nurse educators among low income, ethnic minority seniors with poorly controlled T2DM.

The aims of this randomized controlled efficacy trial are:

Aim 1: To test the efficacy of Home DM-BAT on clinical outcomes (hemoglobin A1c, blood pressure, and LDL-Cholesterol).

Hypothesis 1: Low income, minority seniors with poorly controlled T2DM randomized to Home DM-BAT will have significantly greater improvements in clinical outcomes (hemoglobin A1c, blood pressure, and LDL-Cholesterol) at 12 months of follow-up compared to the control group (in-home, telephone-delivered supportive therapy - ST).

Aim 2: To test the efficacy of Home DM-BAT on behavioral outcomes (home blood glucose monitoring, diet, exercise and medication adherence) and quality of life.

Hypothesis 2: Low income, minority seniors with poorly controlled T2DM randomized to Home DM-BAT will have significantly greater improvements in behavioral outcomes (home blood glucose monitoring, diet, exercise and medication adherence) and quality of life (physical and mental health components of SF-12) at 12 months of follow-up compared to the control group.

Aim 3: To determine the cost-effectiveness of Home DM-BAT intervention for diabetes.

Hypothesis 3: Home DM-BAT will be more cost-effective in improving hemoglobin A1c levels at 12 months of follow-up, compared to the control group, as measured by differences in program costs, resource utilization, and hemoglobin A1c levels.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age >=65 years of age;

  2. Self-identified as Black/African American or Hispanic;

  3. Clinical diagnosis of T2DM verified by an HbA1c >=8% at the screening assessment;

  4. Able to communicate in English or Spanish; and

  5. Resident of independent, subsidized, assisted senior housing facility or communitydwelling elderly adults in the greater Milwaukee area and surrounding counties thathave high African American/Hispanic populations.

Exclusion

Exclusion Criteria:

  1. Mental confusion at screening assessment suggesting significant dementia;

  2. Participation in other diabetes research;

  3. Alcohol or drug abuse/dependency;

  4. Active psychosis or acute mental disorder; and

  5. Life expectancy <12 months at screening assessment.

Study Design

Total Participants: 200
Treatment Group(s): 2
Primary Treatment: Supportive Therapy (Control)
Phase:
Study Start date:
January 03, 2020
Estimated Completion Date:
December 31, 2025

Study Description

Study Overview. Two hundred participants will be randomized 1:1 to Home DM-BAT (n=100) or the control condition (n=100) to control for attention. The intervention includes 8 weekly intervention sessions and 10 monthly booster sessions. Study assessments will be performed by blinded research assistants at baseline, 3-, 6-, 9-, and 12-months of follow-up. Primary analyses will be conducted at 12 months post-randomization.

Description of the Home DM-BAT Intervention: A trained nurse educator will deliver the manualized Home DM-BAT intervention via telephone. Subjects will receive 8-weekly sessions of behavioral activation and monthly booster sessions from months 3-12. All intervention sessions will be delivered by telephone and will include a previously tested diabetes education/skills training intervention based on ADA guidelines, diabetes-tailored behavioral activation and will address social determinant of health issues.

Control Group (GHE+ST): Patients randomized to the control group will receive in-home, telephone-delivered 8-weekly sessions of combined general health education (GHE) and supportive therapy (ST) and monthly booster sessions from months 3-12 to match the intervention group for both content and attention. The control group will not receive diabetes education, address social determinants of health, or behavioral activation.

Connect with a study center

  • State University of New York at Buffalo

    Buffalo, New York 14203
    United States

    Site Not Available

  • Medical College of Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.